Pharmaceutical advances offer new options for health outcomes

Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.

An international study holds promising results for patients suffering from IBS-D. In the phase II study, researchers found that the drug ibodutant significantly improved symptoms in more than 50 percent of the individuals treated.

"While there's been a lot of progress in medicines for IBS with constipation, we haven't seen the same in IBS with diarrhea," said Jan Tack, MD, professor and director of the division of gastroenterology and internal medicine at Leuven University in Belgium. "Up to this point, we haven't been able to provide a pharmaceutical option for this patient group that successfully manages the pain associated with the condition."

IBS is an extremely common condition, affecting an estimated 10 percent of adults. Funded by Menarini, the double-blind, multinational study recruited 559 patients with IBS-D who were randomized and treated with 1, 3 or 10 mg of ibodutant or a placebo. Patients took an once daily for eight consecutive weeks. Researchers found that 10 mg was the most effective dose and that it worked best for females.

"These are exciting findings that could bring a lot of relief to many patients," said Dr. Tack said. "We're looking forward to moving into phase III to confirm our findings with a much larger sample of patients."

New therapy for patients with hepatitis C examined

New research suggests that an investigational therapy for patients with can achieve high response rates in a wide range of patients, even those who respond poorly to current treatments. The study examined the safety and efficacy of -free regimens, including three direct-acting with and without , for 12 or 24 weeks, in patients with who were either treatment-naïve or had previously failed standard treatment with peginterferon and ribavirin.

In the phase II study, researchers found that the treatment regimens achieved high sustained virologic response (SVR) rates, an efficacy measure of a hepatitis C treatment, in non-cirrhotic patients with HCV genotype-1 (GT 1). SVR was achieved by 98.7 percent of treatment-naïve patients and 93.3 percent of prior nonresponders after 12 weeks of treatment with three direct-acting agents with ribavirin.

"Hepatitis C genotype 1 is the most common type of hepatitis in the U.S., and many of these patients are still quite difficult to treat with current interferon-based therapies," said Frederick Nunes, MD, clinical associate professor of medicine at Penn Medicine. "This includes specific populations such as African Americans and patients with high body mass or pre-diabetes. These results suggest that highly effective regimens like this one may overcome that difficulty, without the need for interferon."

Related Stories

Recommended for you

Sierra Leone marks grim Ebola anniversary

date 1 hour ago

On May 24 last year a pregnant woman and an older housewife staggered into Kenema hospital in eastern Sierra Leone and were diagnosed within a day as the country's first Ebola cases.

MSF fighting cholera outbreak in Tanzania refugee camps

date 20 hours ago

Medical charity Medecins sans Frontieres (MSF, Doctors Without Borders) said Sunday it had launched emergency treatment centres in Tanzania, where thousands of Burundians fleeing unrest have been hit by cholera.

Bacteria blamed in indigenous Mexican baby deaths

date May 23, 2015

Bacteria—and not a contaminated vaccine as initially suspected—were to blame for the recent deaths of two Mexican babies and for sickening 29 others, according to an official investigation.

Explainer: What is Chagas disease?

date May 22, 2015

According to an article in the Journal of the American Medical Association (JAMA), in a Los Angeles clinic treating patients with heart failure, about 20% of Latin American patients have Chagas disease. What is that?, y ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.